Market Overview:
The global chronic idiopathic constipation (CIC) drugs market is expected to register a CAGR of 7.5% during the forecast period, 2018-2030. The market growth can be attributed to the increasing prevalence of CIC and rising demand for effective treatment options. Based on type, the global chronic idiopathic constipation (CIC) drugs market is segmented into lubiprostone, linaclotide and others. Lubiprostone dominates the market owing to its high efficacy and safety profile. Linaclotide is expected to grow at a higher rate during the forecast period as it offers better patient compliance than other available therapies. Based on application, hospitals & clinics account for a major share of the global chronic idiopathic constipation (CIC) drugs market followed by ambulatory surgical centres, long term care centres and others segments respectively.
Product Definition:
Chronic idiopathic constipation (CIC) is a type of constipation that is not caused by another medical condition and that has been present for at least 3 months. CIC drugs are used to treat chronic idiopathic constipation.
Lubiprostone:
Lubiprostone is a lubiprotein that works by increasing the frequency of muscle contractions and thereby promotes defecation. Lubiprostone is used in the treatment of CIC as well as irritable bowel syndrome (IBS). It has been approved for use in Europe, Canada, and Australia; however, it has not been approved for use in the U.S. due to its non-availability as a generic medicine till date.
Linaclotide:
Linaclotide is a cyclic peptide with 5-HT2B receptor agonist activity. It is currently under investigation as an anti-emetic for the treatment of cancer nausea and vomiting. Linaclotide has shown promising results in phase II clinical trials for CIC, which makes it an attractive drug candidate to be used in CIC treatment plans.
The global linaclotide market size was valued at USD 31 million in 2018.
Application Insights:
The others segment held the largest share of the global market in 2017. This is due to a high prevalence of chronic diseases such as cancer, Parkinson¢â‚¬â„¢s disease, and Alzheimer¢â‚¬â„¢s disease. As a result, patients suffering from these diseases are highly susceptible to constipation. Lubiprostone is used for treating CIC owing to its ability to stimulate motility and increase defecation frequency in patients with IBD and Crohn¢â‚¬â„¢s disease.
Linaclotide is used for treating slow-moving or non-stooling bowel movements (hard stools) caused by chronic constipation along with other IBS symptoms such as abdominal bloating, nausea/vomiting, stomach pain/cramps and diarrhea in adults & children above 12 years of age.
Regional Analysis:
North America accounted for the largest share of global chronic idiopathic constipation drugs market in 2017. The region is expected to maintain its dominance over the forecast period as well owing to increasing awareness about CIC treatment, presence of key players and availability of effective treatment methods. Moreover, high healthcare expenditure and rising geriatric population are some other factors contributing toward growth in this region.
Asia Pacific is anticipated to be the fastest-growing regional segment during the forecast period due to growing geriatric population, improving lifestyle habits among youth along with increasing healthcare spending capacity in developing economies such as India & China & Indonesia etc. Growing medical tourism industry also contributes towards growth in these regions which can help people suffering from CIC get proper treatment at affordable costs thereby boosting market demand over the coming years.
Growth Factors:
- Increasing prevalence of chronic idiopathic constipation (CIC)
- Growing awareness about the symptoms and treatment of chronic idiopathic constipation (CIC)
- Rising demand for better and more effective treatments for chronic idiopathic constipation (CIC)
- Availability of new drugs and therapies for the treatment of chronic idiopathic constipation (CIC)
- Growing number of clinical studies on new drugs and therapies for the treatment of chronic idiopathic constipation
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Idiopathic Constipation (CIC) Drugs Market Research Report
By Type
Lubiprostone, Linaclotide, Others
By Application
Hospitals & Clinics, Ambulatory Surgical Centres, Long Term Care Centres, Others
By Companies
Actavis, Chugai Pharmaceutical, Ferring International Center, Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding, Sanofi, Bayer, Salix Pharmaceuticals, Actavis, Ironwood Pharmaceuticals, Progenics Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
137
Number of Tables & Figures
96
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Idiopathic Constipation (CIC) Drugs Market Report Segments:
The global Chronic Idiopathic Constipation (CIC) Drugs market is segmented on the basis of:
Types
Lubiprostone, Linaclotide, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals & Clinics, Ambulatory Surgical Centres, Long Term Care Centres, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Actavis
- Chugai Pharmaceutical
- Ferring International Center
- Synergy Pharmaceuticals
- Pfizer
- GlaxoSmithKline
- Roche Holding
- Sanofi
- Bayer
- Salix Pharmaceuticals
- Actavis
- Ironwood Pharmaceuticals
- Progenics Pharmaceuticals
Highlights of The Chronic Idiopathic Constipation (CIC) Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Lubiprostone
- Linaclotide
- Others
- By Application:
- Hospitals & Clinics
- Ambulatory Surgical Centres
- Long Term Care Centres
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Idiopathic Constipation (CIC) Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic idiopathic constipation (CIC) drugs are medications used to treat constipation. These drugs work by helping the body to move more waste through the digestive system.
Some of the major players in the chronic idiopathic constipation (cic) drugs market are Actavis, Chugai Pharmaceutical, Ferring International Center, Synergy Pharmaceuticals, Pfizer, GlaxoSmithKline, Roche Holding, Sanofi, Bayer, Salix Pharmaceuticals, Actavis, Ironwood Pharmaceuticals, Progenics Pharmaceuticals.
The chronic idiopathic constipation (cic) drugs market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Idiopathic Constipation (CIC) Drugs Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Chronic Idiopathic Constipation (CIC) Drugs Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Chronic Idiopathic Constipation (CIC) Drugs Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Chronic Idiopathic Constipation (CIC) Drugs Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Chronic Idiopathic Constipation (CIC) Drugs Market Size & Forecast, 2020-2028 4.5.1 Chronic Idiopathic Constipation (CIC) Drugs Market Size and Y-o-Y Growth 4.5.2 Chronic Idiopathic Constipation (CIC) Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Lubiprostone
5.2.2 Linaclotide
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals & Clinics
6.2.2 Ambulatory Surgical Centres
6.2.3 Long Term Care Centres
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chronic Idiopathic Constipation (CIC) Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chronic Idiopathic Constipation (CIC) Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Lubiprostone
9.6.2 Linaclotide
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals & Clinics
9.10.2 Ambulatory Surgical Centres
9.10.3 Long Term Care Centres
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Lubiprostone
10.6.2 Linaclotide
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals & Clinics
10.10.2 Ambulatory Surgical Centres
10.10.3 Long Term Care Centres
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Lubiprostone
11.6.2 Linaclotide
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals & Clinics
11.10.2 Ambulatory Surgical Centres
11.10.3 Long Term Care Centres
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Lubiprostone
12.6.2 Linaclotide
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals & Clinics
12.10.2 Ambulatory Surgical Centres
12.10.3 Long Term Care Centres
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Lubiprostone
13.6.2 Linaclotide
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals & Clinics
13.10.2 Ambulatory Surgical Centres
13.10.3 Long Term Care Centres
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chronic Idiopathic Constipation (CIC) Drugs Market: Competitive Dashboard
14.2 Global Chronic Idiopathic Constipation (CIC) Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Actavis
14.3.2 Chugai Pharmaceutical
14.3.3 Ferring International Center
14.3.4 Synergy Pharmaceuticals
14.3.5 Pfizer
14.3.6 GlaxoSmithKline
14.3.7 Roche Holding
14.3.8 Sanofi
14.3.9 Bayer
14.3.10 Salix Pharmaceuticals
14.3.11 Actavis
14.3.12 Ironwood Pharmaceuticals
14.3.13 Progenics Pharmaceuticals